Onasemnogene abeparvovec gene replacement therapy for spinal muscular atrophy in children: a Moscow experience

This study presents the findings of a long-term assessment of the efficacy and safety profile of drug OA in pediatric patients across various age groups and functional ability levels, including individuals identified through expanded newborn screening. Younger patients exhibited a significantly lower incidence of adverse events and demonstrated superior therapeutic efficacy. The majority of older children experienced either positive progression or stabilization of their condition, outcomes that were largely contingent upon their initial functional status and the duration of the pre-treatment waiting period.

Authors

Institutions

Publication Details

Journal
S S Korsakov Journal of Neurology and Psychiatry
Published
2025-11-21
DOI
https://doi.org/10.17116/jnevro2025125102103
Primary Topic
Neurogenetic and Muscular Disorders Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Onasemnogene abeparvovec gene replacement therapy for spinal muscular atrophy in children: a Moscow experience

Vera Zarubina, Н. Л. Печатникова, В.В. Горев, A. A. Rakhalina et al.
S S Korsakov Journal of Neurology and Psychiatry
Neurogenetic and Muscular Disorders Research
article

Onasemnogene abeparvovec gene replacement therapy for spinal muscular atrophy in children: a Moscow experience

Vera Zarubina, Н. Л. Печатникова, В.В. Горев, A. A. Rakhalina, С И Валиева, N. A. POLYAKOVA, В. С. Какаулина, Tatiana N. Kekeeva, Yu. E. Martynenko, Анна Владимировна Власова, I.P. Vitkovskaya, Z.I. Esmurzieva, A.A. Chudaykina
article en

Abstract

This study presents the findings of a long-term assessment of the efficacy and safety profile of drug OA in pediatric patients across various age groups and functional ability levels, including individuals identified through expanded newborn screening. Younger patients exhibited a significantly lower incidence of adverse events and demonstrated superior therapeutic efficacy. The majority of older children experienced either positive progression or stabilization of their condition, outcomes that were largely contingent upon their initial functional status and the duration of the pre-treatment waiting period.

S S Korsakov Journal of Neurology and PsychiatryVol. 125(10)
Pirogov Russian National Research Medical University (RU), Central Research Institute (IN), Federal Research Institute for Health Organization and Informatics (RU), Research Centre for Medical Genetics (RU), City Clinical Hospital (RU)
Openalex Percentile: Top 48%
Neurogenetic and Muscular Disorders Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Onasemnogene abeparvovec gene replacement therapy for spinal muscular atrophy in children: a Moscow experience — Vera Zarubina, Н. Л. Печатникова, et al. · S S Korsakov Journal of Neurology and Psychiatry (2025) | TGRS Research Map | TGRS